hackint0sh/New-Dataset huggingface dataset:
However, due to the destruction of the gastric wall structure by neoadjuvant therapy, accurate imaging re staging is difficult. Currently, accurate tumor regression grading can only be obtained through surgical resection of pathological specimens. For cReT after neoadjuvant therapy, the diagnostic accuracy of EUS is only 63% (T2: 44%, T3: 68%, T4: 90%). Due to the presence of chronic inflammatory reactions, such as tumor cell apoptosis, necrosis, fibrosis, etc., in both the tumor and the critical normal gastric wall after neoadjuvant therapy, imaging cannot accurately identify the level of gastric wall, leading to the current low value of CT for cReT. Meanwhile, due to the fact that the pathological reactions of lymph nodes after neoadjuvant therapy are mainly subacute inflammatory reactions accompanied by scar tissue formation, and not all lymph node volumes that experience these pathological reactions will rapidly decrease, the accuracy of CT diagnosis of cReN is only 44%, while the sensitivity and specificity of EUS diagnosis of cReN are 50% and 56%, respectively.
In addition, positron emission tomography (PET) can reflect the abnormal metabolism, protein synthesis, DNA repair, and cell proliferation of tumors at the molecular level, providing important information in tumor grading diagnosis, prognosis evaluation, treatment decision-making, and efficacy monitoring. The conventional positron tracer 18F-FDG can reflect the glucose metabolism ability of different tissues, while most types of malignant tumors exhibit high metabolism. Therefore, 18F-FDG can be used for the diagnosis, staging, and treatment monitoring of cancer. However, in gastric cancer patients, 18F-FDG has certain limitations, including 1) interference with physiological or inflammatory uptake of the gastric wall; 2) Low uptake of 18F-FDG is present in signet ring cell carcinoma, mucinous adenocarcinoma, or other poorly differentiated cancers with high mucus content; 3) There are cases of false positive FDG after immunotherapy. In the study of SUV changes in the tumor area before and after treatment, it was found that patients with postoperative pathological regression grades 1-5 Δ SUVs are between 0-70%.
Tumor associated fibroblasts are closely related to tumor growth, invasion, and distant metastasis, and their activation requires the involvement of fibroblast activation protein (FAP). Therefore, radiolabeled fibroblast activation protein inhibitor (FAPI) can achieve in vivo FAP targeted tracing and quantification by specifically binding to FAP. Currently, a large number of studies have shown that 18F-FAPI is superior to 18F-FDG in the staging and re staging of gastric cancer. Furthermore, prospective studies have shown a certain relationship between tumor regression grade (TRG) and 18F-FAPI rate of change parameters (SUVmax, SUVavg, SUVR).
Therefore, in the early stage of this study, 18F-FAPI combined with 18F-FDG PET/MRI imaging was used to evaluate the efficacy of neoadjuvant therapy for gastric cancer, preoperative assessment of tumor regression grade after treatment, and re staging to guide the development of further clinical treatment plans. conditions: Cancer studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 32 type: ESTIMATED name: 18F-FAPI#18F-FDG measure: Evaluation efficacy of tumor regression level measure: expression of FAP measure: expression of GLUT1 measure: SUV sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Nuclear Medicine, Daping Hospital of Army Medical University status: RECRUITING city: Chongqing state: Chongqing zip: 400010 country: China name: Xiao Chen, Ph.D role: CONTACT phone: 15922970174 email: xiaochen229@foxmail.com lat: 29.56278 lon: 106.55278 hasResults: False
nctId: NCT06327360 id: FDG_ 88-16 briefTitle: Illness Expectations in Pulmonary Fibrosis acronym: CAMFP overallStatus: ENROLLING_BY_INVITATION date: 2023-10-10 date: 2023-10-10 date: 2025-10-01 date: 2024-03-25 date: 2024-04-05 name: Fondazione Don Carlo Gnocchi Onlus class: OTHER name: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico name: FIMARP ONLUS - FEDERAZIONE ITALIANA IPF E MALATTIE POLMONARI RARE briefSummary: This study aims to delve into the constructs of illness beliefs and expectations among patients with Pulmonary Fibrosis, exploring how these beliefs and expectations may influence the treatment journey, including oxygen therapy, non-invasive ventilation therapy, and pharmacological treatments. conditions: Pulmonary Fibrosis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 130 type: ESTIMATED name: Psychological questionnaires measure: Adherence to Pharmacological Treatment measure: Adherence to Oxygen Therapy measure: Adherence to Non invasive ventilation measure: Illness beliefs measure: Pharmacological treatment Beliefs measure: Illness Expectations measure: Illness Cognitions measure: Socio-demographic variables measure: Clinical and medical data sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano city: Milano zip: 20122 country: Italy lat: 45.46427 lon: 9.18951 facility: Don Gnocchi Foundation city: Milano zip: 20148 country: Italy lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06327347 id: 2020-05_C2H briefTitle: Comparative Study of 2 Multifocal Intraocular Lenses in Heidelberg acronym: C2H overallStatus: RECRUITING date: 2022-07-17 date: 2026-03-31 date: 2026-07-31 date: 2024-03-25 date: 2024-03-25 name: Cristalens Industrie class: INDUSTRY briefSummary: The goal of this clinical trial is to compare the performance of 2 intraocular lenses (IOLs): ARTIS SYMBIOSE (study lenses) vs PANOPTIX (comparator) through binocular Distance Corrected Intermediate Visual Acuity (DCIVA) assessed at 80 cm in photopic conditions at minimum 1-month post-operative by a blinded evaluator.
Participants will attend a total of 5 study visits: 1 preoperative visit, 1 surgery visit and 3 postoperative visits. conditions: Cataract studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Parallel Assignement primaryPurpose: TREATMENT masking: SINGLE maskingDescription: The Binocular Distance Corrected Intermediate Visual Acuity (DCIVA) assessed at 80 cm in photopic conditions at minimum 1-month post-operative is perforemd by a blinded evaluator. whoMasked: OUTCOMES_ASSESSOR count: 50 type: ESTIMATED name: intraocular lens implantation in cataract surgery measure: Binocular Distance Corrected Intermediate Visual Acuity sex: ALL minimumAge: 50 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Universitäts-Augenklinik Heidelberg International Vision Correction Research Centre (IVCRC) status: RECRUITING city: Heidelberg country: Germany name: Raquel Willrich Amroussi role: CONTACT phone: +49 6221 56-36849 email: raquel.willrichamroussi@med.uni-heidelberg.de lat: 49.40768 lon: 8.69079 hasResults: False
nctId: NCT06327334 id: 2023/03 briefTitle: Brain Heart InterActioNs in Cardiac Arrest. Ancillary Study of the HEAVENwARd Trial acronym: BHIANCA overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2027-05-15 date: 2027-05-15 date: 2024-03-25 date: 2024-03-25 name: CMC Ambroise Paré class: OTHER briefSummary: Despite advances in post-resuscitation care of patients with cardiac arrest (CA), the majority of survivors who are treated after restoration of spontaneous circulation (ROSC) will have sequelae of hypoxic-ischemic brain injury ranging from mild cognitive impairment to a vegetative state. Current recommendations suggest using a multimodal approach to predict poor prognosis, meaning combining markers together. Yet, a substantial proportion of patients do not have a clear prognostic evaluation even when applying the latest ESICM recommendations algorithm published in 2021. It is therefore important to identify new prognostic markers to predict both unfavorable and favorable outcomes. Data regarding the pathophysiological mechanisms of post-anoxic encephalopathy suggest a diffuse anoxo-ischemic injury. However, post-mortem neuropathology data suggest that these lesions do not uniformly affect neuroanatomical structures, with some regions (especially hippocampal and insular) appearing more sensitive to anoxia. Conversely, the brainstem appears less affected by anoxic lesions. Under physiological conditions, there are interactions between the heart and the brain, and between the brain and the heart mainly related to the autonomic nervous system, through interactions between central cortical control structures (especially insular) and brainstem structures (at the level of the bulb) and peripheral structures of the heart. Exploring the pathophysiological mechanisms of heart-brain interactions post-CA could thus help better understand the pathophysiology of anoxo-ischemic encephalopathy, before considering potential therapeutic targets. Furthermore, this heart-brain dysfunction could have prognostic value. Indeed, recent studies in healthy subjects and patients with consciousness disorders suggest that autonomic nervous system activity measured by brain-heart interactions could be a reliable marker of consciousness and cognitive processing. These coupled heart-brain interactions can be evaluated through synchronous electroencephalogram (EEG) and electrocardiogram (ECG) recordings, as there are coupled interactions between the signals of these two organs. The existence of abnormal brain-heart coupling could be associated, on the one hand, with the severity of post-anoxic encephalopathy, and on the other hand, with neurological prognosis in patients with persistent coma post-CA.
This ancillary study of a multicentre prospective cohort "HEAVENwARd study" (NCT06044922) will assess the prevalence and prognostic value of bilateral brain-heart interactions in comatose patients after CA. conditions: Cardiac Arrest studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 200 type: ESTIMATED measure: Bilateral brain-heart interactions measure: Poor neurological outcome evaluated using the CPC score measure: Mortality measure: Post-anoxic encephalopathy severity evaluated by composite prognostic markers combining EEG patterns, somatosensory evoked potentials (SEP) and neuron specific enolase (NSE). sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Brest University Hospital city: Brest state: Bretagne zip: 29609 country: France name: Pierre BAILLY, MD role: CONTACT email: pierre.bailly@chu-brest.fr name: Pierre BAILLY, MD role: PRINCIPAL_INVESTIGATOR lat: 48.3903 lon: -4.48628 facility: Ambroise Paré - Hartmann Private Hospital Group city: Neuilly-sur-Seine state: Ile-de-France zip: 92200 country: France name: Guillaume GERI, MD, PhD role: CONTACT email: guillaume.geri@clinique-a-pare.fr name: Guillaume GERI, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 48.8846 lon: 2.26965 facility: Cochin Hospital city: Paris state: Ile-de-France zip: 75014 country: France name: Alain CARIOU, MD, PhD role: CONTACT email: alain.cariou@aphp.fr name: Alain CARIOU, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 48.85341 lon: 2.3488 facility: Nantes University Hospital city: Nantes state: Pays De La Loire zip: 44093 country: France name: Jean-Baptiste LASCARROU, MD role: CONTACT email: jeanbaptiste.lascarrou@chu-nantes.fr name: Jean-Baptiste LASCARROU, MD role: PRINCIPAL_INVESTIGATOR lat: 47.21725 lon: -1.55336 facility: Marseille University Hospital city: Marseille state: Provence-Alpes-Côte d'Azur zip: 13005 country: France name: Jeremy BOURENNE, MD role: CONTACT email: jeremy.bourenne@ap-hm.fr name: Jeremy BOURENNE, MD role: PRINCIPAL_INVESTIGATOR lat: 43.29551 lon: 5.38958 hasResults: False
nctId: NCT06327321 id: 23-PP-08 briefTitle: Vitiligo Treatment by Targeting TYK2 Mediated Responses acronym: ViTYK overallStatus: RECRUITING date: 2024-05-05 date: 2026-05-05 date: 2026-11-05 date: 2024-03-25 date: 2024-04-12 name: Centre Hospitalier Universitaire de Nice class: OTHER briefSummary: Vitiligo affects approximately 1 to 2% of the global population and significantly impacts people's quality of life. Achieving the best treatment outcomes for vitiligo involves addressing the autoimmune inflammatory response to stop the depigmentation process and promoting the differentiation of melanocyte stem cells to induce repigmentation. The loss of melanocytes in vitiligo is a result of an autoimmune process. While the IFN gamma pathway plays a crucial role in the adaptive immune response in vitiligo, there is increasing evidence highlighting the importance of the innate immune response. Deucravacitinib, an allosteric TYK2 inhibitor, has shown effectiveness and safety in treating psoriasis. It inhibits the responses of IFN alpha (IFNα), IFN beta (IFNβ), and IL12, and may also have an impact on the Th1 response. The hypothesis is that by targeting the IFN type I response and IL12, deucravacitinib could effectively halt the depigmentation process and facilitate repigmentation of vitiligo lesions. When combined with NB-UVB, the process of repigmentation should be significantly enhanced. The primary objective is to compare the proportion of patients treated with deucravacitinib versus placebo achieving VITIL-IA 50 at week 24.
Interventions Following central randomization, patients will be assigned to receive either deucravacitinib 12mg daily (QD) or a placebo daily (QD) for a duration of 24 weeks. At the end of this period, patients will be re-randomized to receive either deucravacitinib 12mg QD alone or deucravacitinib 12mg QD + twice weekly narrowband UVB treatment twice weekly for an additional 24 weeks.
Throughout the study, there will be a total of six visits conducted: selection, inclusion, Week 12, Week 24, Week 36, and Week 48. In patients who volunteer, a skin biopsy will be performed on both the lesional and peri-lesional areas at baseline, Week 12 and Week 36. Serum and plasma samples will be collected at the screening visit, Week 12, Week 24, Week 36, and Week 48. conditions: Vitiligo, Generalized studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 128 type: ESTIMATED name: Deucravacitinib name: Volunteer without treatment measure: rate of depigmentation measure: number of patient with the T-VASI 50 sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CHU de Nice - Hôpital de l'Archet status: RECRUITING city: Nice state: Alpes-Maritimes zip: 06200 country: France name: Passeron Thierry, PhD role: CONTACT phone: +33492036488 email: passeron.t@chu-nice.fr name: pradelli Emmanuelle role: CONTACT phone: +33492036488 email: pradelli.e@chu-nice.fr name: Thierry Passeron, PhD role: PRINCIPAL_INVESTIGATOR lat: 43.70313 lon: 7.26608 facility: APHP, Henri Mondor status: NOT_YET_RECRUITING city: Paris state: Creteil country: France name: Khaled EZZEDINE, PhD role: CONTACT email: khaled.ezzedine@aphp.fr name: Khaled EZZEDINE, PhD role: PRINCIPAL_INVESTIGATOR lat: 48.85341 lon: 2.3488 facility: CHU de Bordeaux status: NOT_YET_RECRUITING city: Bordeaux state: Talence zip: 33000 country: France name: Julien Seneschal, PhD role: CONTACT email: julien.seneschal@chu-bordeaux.fr name: Julien Seneschal, PhD role: SUB_INVESTIGATOR lat: 44.84044 lon: -0.5805 facility: CHU de Lille status: NOT_YET_RECRUITING city: Lille country: France name: Laurent MORTIER, PhD role: CONTACT email: Laurent.MORTIER@chu-lille.fr name: Laurent MORTIER, PhD role: SUB_INVESTIGATOR lat: 50.63297 lon: 3.05858 facility: HCL status: NOT_YET_RECRUITING city: Lyon country: France name: Cécile LESORT, PhD role: CONTACT email: cecile.lesort@chu-lyon.fr name: Cécile Lesort, PhD role: SUB_INVESTIGATOR lat: 45.74848 lon: 4.84669 hasResults: False
nctId: NCT06327308 id: 2023/803 briefTitle: Evaluation of Cirrhotic Cardiomyopathy by Cardiac MRI in Patients Waiting for Liver Transplant. acronym: CARDIOFIBROCIR overallStatus: NOT_YET_RECRUITING date: 2024-03-31 date: 2025-03-31 date: 2027-12-31 date: 2024-03-25 date: 2024-03-27 name: Centre Hospitalier Universitaire de Besancon class: OTHER briefSummary: The aim of this multicenter prospective observational pilot study is to describe the evolution of myocardial fibrosis in cirrhotic patients before and after liver transplantation (LT). Through multimodal analysis of myocardial function and architecture, and analysis of specific markers of inflammation, we aim to explore the following hypotheses: 1) systemic inflammation promotes myocardial fibrosis in cirrhotic patients and could be an early marker of cirrhotic cardiomyopathy; 2) LT allows resolution of myocardial fibrosis by preventing the bacterial translocation that favors the development of deleterious systemic inflammation. conditions: Cirrhosis studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 60 type: ESTIMATED name: MRI name: Blood sampling measure: Primary outcome measure measure: Prevalence of cirrhotic cardiomyopathy according to 2019 criteria [Izzy M, et al. Hepatology 2020;71:334-45], echocardiographic signs of left ventricular systolic and diastolic dysfunction : measure: Analysis of the association between myocardial extracellular volume (MECV) (explained variable) and plasma 3-HM concentration (explanatory variable). measure: Analysis of the association between myocardial extracellular volume (MECV) and the concentration of markers of inflammation (CRP, procalcitonin, copeptin, IL-6) and proteins modulating the degree of inflammation (LBP, PLTP, CETP). measure: Analysis of the association between the difference in MECV in transplant recipients between visit 2 and visit 3 according to the degree of immunosuppression, measured by mean residual tacrolemia in the 12 months post-LT. measure: Number, type and cumulative incidence of cardiovascular events (heart failure, rhythm disorders, etc.) according to cirrhotic cardiomyopathy status occurring between inclusion and LT. measure: Number, type and cumulative incidence of cardiovascular events (heart failure, rhythm disorders, etc.) occurring between inclusion and LT, according to cirrhotic cardiomyopathy status. sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CHU Besancon - Hopital Minjoz city: Besançon zip: 25000 country: France name: Delphine WEIL, MD, PHD role: CONTACT lat: 47.24878 lon: 6.01815 facility: CHU Dijon - Hopital François Mitterrand city: Dijon zip: 21000 country: France name: Marianne LATOURNERIE, MD role: CONTACT lat: 47.31667 lon: 5.01667 facility: CHRU Nancy - Hôpital de Brabois city: Nancy zip: 54000 country: France name: Mouni BENSENANE -OUSSALAH, MD role: CONTACT lat: 48.68439 lon: 6.18496 facility: CHU Strasbourg - Hopital de HautePierre city: Strasbourg zip: 67000 country: France name: Camille BESCH, MD role: CONTACT lat: 48.58392 lon: 7.74553 hasResults: False
nctId: NCT06327295 id: ATB1651-102 briefTitle: A Study of ATB1651 in Adults With Mild to Moderate Onchomycosis overallStatus: NOT_YET_RECRUITING date: 2024-03-30 date: 2025-06-30 date: 2026-01-30 date: 2024-03-25 date: 2024-03-25 name: AmtixBio Co., Ltd. class: INDUSTRY briefSummary: The study is designed to evaluate the Safety, Tolerability and Pharmacokinetics of ATB1651 in participants with mild to moderate onychomycosis conditions: Onychomycosis studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 120 type: ESTIMATED name: ATB1651-102- Cohort 1 name: ATB1651-102- Cohort 2 name: ATB1651-102- Cohort 3 name: ATB1651-102- Cohort 4 name: Placebo measure: To evaluate the complete cure rate with topical ATB1651 3% and ATB1651 5% in participants with mild to moderate onychomycosis. measure: To further evaluate the efficacy of topical ATB1651 3% and topical ATB1651 5% in participants with mild to moderate onychomycosis. measure: To assess and collect the percentage and severity of adverse events (AEs). measure: Maximum plasma concentration (Cmax) measure: Time to maximum plasma concentration (Tmax) measure: Apparent terminal elimination rate constant (λz) measure: Area under curve (AUC) measure: Apparent terminal half-life (t 1/2) measure: Apparent clearance (CL) measure: Apparent terminal volume of distribution (VD) measure: Plasma ATB1651 trough concentrations (Ctrough) sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: New Zealand Clinical Research Christchurch city: Christchurch zip: 8011 country: New Zealand name: Corey Sellwood, Dr role: CONTACT phone: +64 800 862 278 name: Corey Sellwood, Dr role: PRINCIPAL_INVESTIGATOR lat: -43.53333 lon: 172.63333 hasResults: False
nctId: NCT06327282 id: ChinaPLAGHPAIN briefTitle: the Effect of Preoperative Pain Education by Anesthesia Nurses on Postoperative Pain Among Adult Patients Undergoing Abdominal Surgery overallStatus: NOT_YET_RECRUITING date: 2024-04-20 date: 2025-01-01 date: 2025-04-04 date: 2024-03-25 date: 2024-04-16 name: Chinese PLA General Hospital class: OTHER briefSummary: To explore the effects of preoperative pain education on postoperative pain among patients undergoing abdominal surgery. conditions: Postoperative Pain studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 116 type: ESTIMATED name: education on pain and related knowledge measure: Occurrence of pain measure: Mastery of the use of patient-controlled analgesia pump measure: Patient satisfaction with postoperative analgesia measure: Adverse events of patients using analgesic pump were recorded measure: The number of times that the analgesic pump was pressed during each 24h and the amount of analgesic pump remaining at this time were recorded measure: The use of rescue analgesics after surgery measure: The postoperative sleep status of patients was evaluated sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06327269 id: MOHW111-TDU-B-221-114009 briefTitle: Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular Carcinoma overallStatus: RECRUITING date: 2021-04-01 date: 2024-12 date: 2026-12 date: 2024-03-25 date: 2024-04-18 name: Chang Gung Memorial Hospital class: OTHER name: Ministry of Health and Welfare, Taiwan briefSummary: The challenge of LDLT to HCC is that tumors with a high risk of recurrence have a high rate of recurrence after liver transplantation, and there is no appropriate treatment to prevent HCC recurrence after transplantation in these patients. Using the advance proton therapy or yttrium 90 as a more aggressive down-staging therapy may contribute to change tumor behavior. It can be used to get a better treatment response and tumor necrosis before LDLT. As a result, it will improve recurrence-free survival and overall survival rate, especially in high-risk groups. In addition, lenvatinib is approved for using in patients with advanced liver cancer because its overall survival rate is not less than sorafenib in clinical trials. A new generation of targeted therapies will be applied to adjuvant therapy after LDLT. conditions: High Risk of Recurrence studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: NONE count: 40 type: ESTIMATED name: Lenvatinib 10 mg measure: Recurrence-free survival with adjuvant therapy sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Surgery status: RECRUITING city: Kaohsiung zip: 833 country: Taiwan name: Chih-Che Lin, Ph.D role: CONTACT phone: +88677317123 phoneExt: 8880 email: chihchelin@cgmh.org.tw name: I-Hsuan Chen, Ph.D role: CONTACT phone: +88677317123 phoneExt: 8582 email: ann0401@cgmh.org.tw lat: 22.61626 lon: 120.31333 hasResults: False